0000000000535825

AUTHOR

Markus Graefen

showing 4 related works from this author

Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy.

2017

Objective To evaluate the impact of preoperative risk category on metastatic disease and prostate cancer-specific mortality (CSM) in patients with prostate cancer (PCa) with adverse pathology at radical prostatectomy (RP). Patients and Methods The records of 6 943 patients who underwent RP at a European tertiary centre were analysed. Biochemical recurrence (BCR), metastatic disease and CSM were assessed for patients with adverse pathology at RP, and stratified according to preoperative low- vs intermediate-/high-risk PCa groups. Kaplan–Meier, cumulative incidence, Cox regression and competing risk regression analyses were performed. Results In patients with extracapsular extension, the meta…

Biochemical recurrenceMalemedicine.medical_specialtyPathologyUrologymedicine.medical_treatment030232 urology & nephrologyUrologyKaplan-Meier EstimateLower riskCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineRisk FactorsMedicineHumansCumulative incidencePathologicalAgedProstatectomybusiness.industryProportional hazards modelProstatectomyHazard ratioProstatic NeoplasmsMiddle AgedProstate-Specific Antigenmedicine.disease030220 oncology & carcinogenesisMultivariate AnalysisbusinessBJU international
researchProduct

A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis

2001

BACKGROUND The aim was to evaluate the clinical performance of alpha1-antichymotrypsin prostate-specific antigen (PSA-ACT) for early diagnosis of prostate cancer (PCa) in a multicenter trial. METHODS Three hundred sixty-seven white men with PCa and 290 with benign prostatic hyperplasia (BPH) with tPSA concentrations between 2 and 20 μg/L were analyzed. The Elecsys system 2010 (Roche Diagnostics, Germany) was used for determination of total PSA (tPSA) and free PSA (fPSA). The PSA-ACT test was a prototype assay used on the ES system (Roche Diagnostics). RESULTS The median concentrations of tPSA (PCa: 8.43 μg/L vs. BPH: 6.60 μg/L) and PSA-ACT (8.30 μg/L vs. 6.46 μg/L) were significantly differ…

AdultMalemedicine.medical_specialtyalpha 1-AntichymotrypsinUrologyProstatic HyperplasiaUrologyEnzyme-Linked Immunosorbent Assayurologic and male genital diseasesStatistics NonparametricProstate cancerProstateMulticenter trialmedicineHumansProtease InhibitorsAlpha1 AntichymotrypsinAgedAged 80 and overGynecologyReceiver operating characteristicbusiness.industryArea under the curveAntibodies MonoclonalProstatic NeoplasmsMiddle AgedProstate-Specific Antigenmedicine.diseaseClinical trialProstate-specific antigenmedicine.anatomical_structureROC CurveOncologybusinessThe Prostate
researchProduct

Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment

2019

Background: Active surveillance (AS) has been increasingly proposed as the preferential initial management strategy for low-risk prostate cancer (PC), while in high-risk PC the indication for surgery has widened. Objective: To evaluate the development of risk group distribution of patients undergoing radical prostatectomy (RP). Design, setting, and participants: Retrospective database review of combined RP databases (2000-2015) of four large European centers (Créteil, Paris; San Rafaele, Milan; Martini Klinik, Hamburg; NKI, AvL, Amsterdam). Outcome measurements and statistical analysis: Clinical and pathological characteristics per year of surgery. Eligibility for AS was defined according …

Malemedicine.medical_specialtymedicine.medical_treatmentUrology030232 urology & nephrologyRisk classificationDiseaseActive surveillanceRisk AssessmentTreatment trend03 medical and health sciencesProstate cancer0302 clinical medicineRisk groupsInternal medicineHumansMedicineDistribution (pharmacology)Watchful WaitingPathologicalRetrospective StudiesProstatectomyProstate cancerbusiness.industryProstatectomyProstatic NeoplasmsCancerProstate-Specific Antigenmedicine.diseaseTailored treatmentRadical prostatectomySurgeryEurope030220 oncology & carcinogenesisNeoplasm Gradingbusiness
researchProduct

Antimicrobial Lubricant Did Not Reduce Infection Rate in Transrectal Biopsy Patients in a Large Randomized Trial Due to Low Complication Rates

2018

Abstract Background Transrectal prostate biopsy (pbx) is the most frequent outpatient procedure in the urological field. Septic complications are a major health issue. Objective To evaluate complication rates with or without an antimicrobial lubricant. Design, setting, and participants A total of 1000 patients received pbx between 2013 and 2015. Information about complications was collected by a 3-wk questionnaire. Return rate was 73.2% (n = 732). Intervention Randomization for pbx with the instillation of an antimicrobial lubricant (intervention group, n = 385) or the standard lubricant (control group, n = 347) was performed. Outcome measurements and statistical analysis Multivariable anal…

Image-Guided BiopsyMalemedicine.medical_specialtyProstate biopsyFeverUrology030232 urology & nephrologyPatient ReadmissionHematospermialaw.invention03 medical and health sciencesPostoperative Complications0302 clinical medicineRandomized controlled triallawGermanyInternal medicineBiopsymedicineHumansProspective StudiesAgedHematuriaLubricantsmedicine.diagnostic_testbusiness.industryUrinary retentionProstateRectumProstatic NeoplasmsAntibiotic ProphylaxisHemospermiaUrinary RetentionAnti-Bacterial AgentsTransrectal biopsy030220 oncology & carcinogenesisInternational Prostate Symptom Scoremedicine.symptomGastrointestinal HemorrhageComplicationbusinessEuropean Urology Focus
researchProduct